A 2022 study estimates that at-home flu tests have a sensitivity of about 63% if the test is performed within 72 hours of ...
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...
Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services ...
Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis: Salt Lake City Wednesday, December 31, 2025, 11:00 Hrs ...
WHO noted that prequalified tests can now be prioritized in pooled procurement mechanisms, which help lower prices, stabilize ...
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.
In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...
WHO has prequalified two Covid-19 rapid antigen tests for the first time, confirming long-term quality and enabling UN ...
CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.
Health and Me on MSN
WHO approves two COVID-19 rapid antigen tests, check the details here
SD Biosensor STANDARD Q and ACON Flowflex—after their earlier emergency use during the pandemic. The move confirms long-term ...
Roche’s cobas liat Bordetella test earns FDA clearance, delivering accurate whooping cough results in 15 minutes.
WHO prequalifies the first two rapid antigen detection tests for Covid-19: Geneva Saturday, December 27, 2025, 11:00 Hrs [IST] The World Health Organization (WHO) announced the pr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback